Biogen Idec began a double-blind, placebo-controlled Phase Ib trial

Biogen Idec began a double-blind, placebo-controlled Phase Ib trial to evaluate multiple doses of IV BIIB037 in about 120 patients with prodromal or mild AD. The Phase 1 study compares six doses of BIIB037 to placebo given as a single intravenous infusion in 56 people with mild to moderate Alzheimer’s. The doses ranged from 0.3 mg/kg to 30 mg/kg.